{"gene":"PROS1","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1981,"finding":"Protein S (encoded by PROS1) exists in two forms in plasma: free protein and in a high-molecular-weight complex with complement component C4b-binding protein (C4BP), held together by noncovalent bonds; a major proportion of C4BP in plasma is complexed with protein S, establishing that protein S is a binding partner for C4BP.","method":"Barium citrate adsorption, SDS-PAGE with and without reduction, biochemical fractionation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original biochemical reconstitution and fractionation, foundational paper replicated extensively","pmids":["6454142"],"is_preprint":false},{"year":1984,"finding":"Protein S functions as a cofactor for activated protein C (APC), which inhibits blood clotting at the levels of factors V and VIII; deficiency of protein S leads to inadequate anticoagulant regulation and recurrent venous thromboembolism, establishing protein S's essential role in the protein C anticoagulant pathway.","method":"Functional assay for protein S activity in plasma, clinical phenotype in protein S-deficient patients","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 — functional assay with defined cellular/biochemical phenotype, foundational paper widely replicated","pmids":["6239102"],"is_preprint":false},{"year":1986,"finding":"Human protein S is a single-chain 635-amino-acid vitamin K-dependent plasma protein with an N-terminal Gla domain, a thrombin-sensitive region, four EGF-like repeat domains, and a C-terminal region homologous to androgen-binding proteins/SHBG; it is structurally distinct from other vitamin K-dependent coagulation proteins in lacking a serine protease domain.","method":"cDNA cloning and sequencing of human liver cDNA library, comparison to bovine protein S sequence","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — primary sequence determination by cDNA cloning, foundational structural paper","pmids":["2944113"],"is_preprint":false},{"year":1986,"finding":"Bovine protein S primary structure confirmed by cDNA sequencing and protein sequencing: single polypeptide of 634 amino acids, one asparagine-linked carbohydrate, a Gla domain, thrombin-sensitive region (residues 42–75), four EGF-like cysteine-rich repeats, and a C-terminal SHBG-homologous domain; cofactor function for activated protein C in inactivation of coagulation factors Va and VIIIa established.","method":"Full-length cDNA sequencing from bovine liver library and direct protein sequencing (95% coverage)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstituted structural and sequence data with protein sequencing validation","pmids":["2940598"],"is_preprint":false},{"year":1990,"finding":"The human protein S expressed gene (PROS1/PS-alpha) spans >80 kb with 15 exons and 14 introns; exons I–VIII encode the vitamin K-dependent module (Gla domain, EGF-like repeats) with intron positions identical to other vitamin K-dependent coagulation proteins, while exons IX–XV encode the SHBG-homologous domain with identical intron positions as the SHBG gene, revealing its mosaic evolutionary origin. A pseudogene (PS-beta) with 97% coding identity but multiple frameshifts/stop codons was also characterized.","method":"Genomic clone isolation, restriction mapping, exon–intron sequencing, comparative genomic analysis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct genomic sequencing and structural characterization","pmids":["2148110"],"is_preprint":false},{"year":1991,"finding":"Protein S acts as a cofactor for activated protein C (APC) in the degradation of phospholipid-bound coagulation factors Va and VIIIa; protein S contains post-translational modifications including 11 Gla residues, beta-hydroxylated Asp in EGF1 and beta-hydroxylated Asn in EGF2–4; calcium binds with high affinity to EGF-like domains playing a structural/stabilizing role; the C4BP-complexed form of protein S lacks APC cofactor function; C4BP beta-chain contains the single protein S binding site.","method":"Protein biochemistry, domain characterization, complex reconstitution, cofactor activity assays","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biochemical assays, domain mapping of post-translational modifications and binding sites","pmids":["1833851"],"is_preprint":false},{"year":1992,"finding":"In plasma, free protein S (~38% of total, ~131 nmol/L) and C4BP-bound protein S (~62%) coexist in a 1:1 molar stoichiometry with C4BP beta-chain; free C4BP predominantly lacks the beta-chain; plasma levels of C4BP beta-chain directly and stoichiometrically regulate free protein S levels; free protein S antigen correlates with protein S anticoagulant activity.","method":"Immunoadsorption with anti-C4BP and anti-protein S antibody-Sepharose columns, ELISA quantitation in human plasma samples","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — quantitative immunoadsorption and ELISA, stoichiometric binding demonstrated","pmids":["1534488"],"is_preprint":false},{"year":1993,"finding":"Protein S directly binds to Factor Va in a calcium-dependent, saturable, and reversible manner (Kd ~33 nM in fluid phase); protein S competes with prothrombin for binding to Factor Va; protein S inhibits prothrombinase activity independently of activated protein C, by a mixed inhibition mechanism, with ~50% inhibition at ~16 nM protein S.","method":"Solid-phase binding assay (immobilized factor Va/protein S), fluid-phase binding with biotin-labeled factors, prothrombinase activity assay with purified clotting factors","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro binding and functional assay, multiple orthogonal methods","pmids":["8428962"],"is_preprint":false},{"year":1994,"finding":"Protein S directly binds to Factor Xa (Kd ~18–19 nM), inhibits Factor Xa amidolytic activity (~50% at 33 nM), and inhibits prothrombin conversion to thrombin by Factor Xa in a phospholipid-independent, Ca2+-stimulated manner; these anticoagulant mechanisms are independent of activated protein C and involve direct interactions with both Factor Xa and Factor Va.","method":"Ligand blotting, solid-phase and fluid-phase binding assays, factor Xa amidolytic activity assay, prothrombin conversion assay, one-stage clotting assay in protein S-depleted plasma","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — multiple in vitro reconstituted assays with purified components, replicated binding by multiple methods","pmids":["8146182"],"is_preprint":false},{"year":2001,"finding":"Four novel PROS1 missense mutations (W108C, W342R, E349K, L485S) and one 4-bp deletion causing frameshift in codons 632–633 cause Type I or III protein S deficiency; platelet mRNA analysis showed mutant transcripts are expressed, suggesting the primary molecular mechanism is defective protein folding/instability and impaired secretion with intracellular degradation, rather than absence of mRNA.","method":"DNA sequencing of PROS1, haplotype analysis with microsatellite markers, platelet mRNA analysis, computer-based structural modeling of protein S","journal":"Thrombosis and haemostasis","confidence":"Medium","confidence_rationale":"Tier 2–3 — mRNA expression analysis plus structural modeling, single lab but multiple methodological approaches","pmids":["11776305"],"is_preprint":false},{"year":2002,"finding":"Protein S binds to phosphatidylserine (PS) exposed on the surface of apoptotic cells and stimulates macrophage phagocytosis of apoptotic cells; immunodepletion of protein S from serum eliminated the pro-phagocytic activity of serum, identifying protein S as the serum factor responsible for serum-enhanced clearance of apoptotic cells.","method":"Protein purification from serum, immunodepletion of protein S, macrophage phagocytosis assay with apoptotic lymphoma cells, phosphatidylserine binding assay","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1–2 — purified protein functional reconstitution, immunodepletion confirmation, multiple assays","pmids":["12447359"],"is_preprint":false},{"year":2003,"finding":"Protein S circulates ~40% as free PS and ~60% complexed with C4BP; the PS–C4BP complex binds to apoptotic cells, positioning C4BP as a bridge between coagulation and complement regulation; complexed protein S loses APC cofactor function while C4BP modulates APC anticoagulant activity.","method":"Review/synthesis of biochemical binding studies, complement activation assays, apoptotic cell binding experiments","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — synthesis of experimental evidence from multiple studies","pmids":["12907438"],"is_preprint":false},{"year":2006,"finding":"Protein S specifically stimulates inhibition of the tissue factor (TF) pathway by promoting the interaction between full-length TF pathway inhibitor (TFPI) and Factor Xa (FXa); protein S causes a 10-fold reduction in the Ki of the FXa/TFPI complex (from 4.4 nM to 0.5 nM), accelerating feedback inhibition of the TF-mediated coagulation pathway and acting in concert with TFPI independently of activated protein C.","method":"Purified component in vitro coagulation assays, kinetic analysis of FXa inhibition by TFPI in presence/absence of protein S, thrombin generation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro assay with purified proteins, kinetic parameters determined","pmids":["16488980"],"is_preprint":false},{"year":2009,"finding":"Gross copy number variations (CNVs) in PROS1—including complete gene deletions, partial deletions (exons 4–9 or 9–11), and partial duplications—account for protein S deficiency in approximately one-third of point mutation-negative hereditary PS-deficient patients, identified by MLPA and confirmed by quantitative PCR.","method":"Multiplex ligation-dependent probe amplification (MLPA), quantitative PCR confirmation, family member testing","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 2 — two orthogonal CNV detection methods, multiple independent probands","pmids":["19466456"],"is_preprint":false},{"year":2013,"finding":"T cell-derived Protein S (Pros1) signals through TAM receptor tyrosine kinases (specifically on dendritic cells) to limit the magnitude of DC activation; genetic ablation of Pros1 in mouse T cells increased expression of costimulatory molecules and cytokines in DCs, enhanced immune responses to T cell-dependent antigens, and increased colitis severity, revealing a homeostatic negative feedback mechanism between adaptive and innate immunity.","method":"Conditional Pros1 knockout in T cells (mouse), DC activation assays, cytokine measurement, colitis model, human PROS1 expression in activated T cells confirmed","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with defined cellular phenotype, multiple immune readouts, human relevance confirmed","pmids":["23850380"],"is_preprint":false},{"year":2016,"finding":"PROS1 knockdown in LN18 glioblastoma cells (siRNA) induces apoptosis via activation of both extrinsic (FasL/death receptor) and intrinsic apoptotic pathways, reduces migration and invasion (by up to 82%), and reduces proliferation; PROS1 silencing also downregulates GAS6 and other TAM family receptors, suggesting PROS1 promotes GBM cell survival through the TAM signaling axis.","method":"siRNA knockdown in LN18 GBM cells, apoptosis assays, wound-healing assay, invasion assay, proliferation assay, expression analysis","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 — siRNA loss-of-function with multiple functional readouts, single lab","pmids":["27840905"],"is_preprint":false},{"year":2018,"finding":"Tumor-secreted Protein S (Pros1) inhibits macrophage M1 polarization (suppressing IFN-γ/LPS-induced M1 cytokine expression) via Mer and Tyro3 (but not Axl) TAM receptors; this suppressive action requires PTP1b complexing with Mer; CRISPR deletion of Pros1 in tumor cells abrogated M1 suppression; IFN-γ induces Pros1 transcription and secretion in tumor cells; Pros1-deficient tumors showed increased innate and adaptive immune infiltration and improved survival in mice.","method":"CRISPR-based Pros1 deletion in tumor cells, Mer/Tyro3/Axl-KO macrophages, PTP1b-KO macrophages, in vitro M1 polarization assay, in vivo tumor survival experiments, cytokine measurement","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic KO models (CRISPR, receptor KO, PTP1b KO), in vitro and in vivo, orthogonal approaches","pmids":["29708510"],"is_preprint":false},{"year":2019,"finding":"Tumor-secreted ProS1 activates Tyro3 and stimulates Erk phosphorylation more potently than Gas6; in cells expressing Tyro3 alone (MGH-U3), ProS1 additionally activates Akt; Gas6 is the sole stimulator of Axl and Akt in cells co-expressing Axl; ProS1 protects cancer cells from staurosporine-induced and serum starvation-induced apoptosis through Tyro3–Erk (and Akt where Tyro3 is sole TAM receptor) signaling.","method":"Western blotting of kinase phosphorylation, conditioned medium experiments, ProS1 ligand traps and warfarin specificity controls, apoptosis assays in multiple cancer cell lines","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2–3 — multiple cell lines and ligand specificity controls, but single lab","pmids":["31766614"],"is_preprint":false},{"year":2021,"finding":"Myeloid cell-derived PROS1 suppresses metastatic seeding in lung and breast cancer models; PROS1 deletion in myeloid cells (cKO) elevated TNF-α, IL-6, Nos2, and IL-10 via modulation of Socs3/NF-κB; cKO BMDM conditioned medium enhanced EMT and activated ERK, AKT, and STAT3 in tumor cells promoting IL-10-dependent invasion; MERTK kinase activity mediates PROS1 suppression of TNF-α and IL-6 but not IL-10; PROS1/MERTK axis in macrophages modulates T cell proliferation and DC costimulatory molecule expression.","method":"Myeloid-specific Pros1 conditional knockout mouse, BMDM conditioned medium experiments, lung and breast metastasis models, cytokine and signaling pathway analysis, MERTK kinase inhibition","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific genetic KO with in vivo metastasis phenotype, multiple orthogonal mechanistic analyses","pmids":["33848267"],"is_preprint":false},{"year":2022,"finding":"BAP1 loss in uveal melanoma leads to epigenetic upregulation of PROS1 (accumulation of H3K27ac at the PROS1 locus per ChIP-seq); elevated tumor-secreted PROS1 activates MERTK (increased phosphorylation) in CD163+ macrophages, promoting an immunosuppressive M2-polarized tumor microenvironment; PROS1 depletion in BAP1-/- uveal melanocytes blocked MERTK phosphorylation in co-cultured macrophages.","method":"ChIP-seq (H3K27ac), RNA-seq and single-cell RNA-seq, co-culture MERTK phosphorylation assay, siRNA PROS1 depletion, multicolor immunohistochemistry on patient tumors","journal":"Cancers","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP-seq, scRNA-seq, functional co-culture, IHC), mechanistic link established","pmids":["35954340"],"is_preprint":false}],"current_model":"PROS1 (Protein S) is a multifunctional vitamin K-dependent plasma glycoprotein with a Gla domain, thrombin-sensitive region, four EGF-like domains, and an SHBG-homologous C-terminal domain; it acts as an anticoagulant cofactor for activated protein C (facilitating degradation of factors Va and VIIIa), directly inhibits Factor Xa and prothrombinase independently of APC, enhances TFPI-mediated suppression of the tissue factor pathway, circulates ~40% free and ~60% in complex with C4BP (which abrogates its APC cofactor function), binds phosphatidylserine on apoptotic cells to stimulate macrophage phagocytic clearance, and signals through TAM receptor tyrosine kinases (Mer, Tyro3) on immune cells (dendritic cells, macrophages) to suppress inflammatory cytokine production and modulate innate and adaptive immune responses, including restraining tumor-associated macrophage M1 polarization and metastasis."},"narrative":{"teleology":[{"year":1981,"claim":"The discovery that Protein S circulates in both free and C4BP-complexed forms established that its bioavailability is regulated by a stoichiometric interaction with complement component C4BP, linking coagulation and complement systems.","evidence":"Biochemical fractionation, barium citrate adsorption, and SDS-PAGE of human plasma","pmids":["6454142"],"confidence":"High","gaps":["Functional consequence of C4BP binding on Protein S activity was not yet determined","Identity of the C4BP subunit mediating the interaction was unknown"]},{"year":1984,"claim":"Demonstration that Protein S is an essential cofactor for APC-mediated inactivation of factors Va and VIIIa, and that its deficiency causes venous thromboembolism, established the physiological anticoagulant role of PROS1.","evidence":"Functional protein S activity assay in plasma from deficient patients, clinical phenotyping","pmids":["6239102"],"confidence":"High","gaps":["Mechanism of cofactor enhancement of APC activity was unresolved","Whether Protein S had APC-independent anticoagulant activity was unknown"]},{"year":1986,"claim":"Cloning of human and bovine PROS1 cDNA revealed a unique multi-domain architecture—Gla domain, thrombin-sensitive region, four EGF-like repeats, and an SHBG-homologous C-terminus—that distinguishes it from serine protease coagulation factors and explains its non-enzymatic cofactor function.","evidence":"cDNA cloning from human and bovine liver libraries, direct protein sequencing (bovine)","pmids":["2944113","2940598"],"confidence":"High","gaps":["Functions of individual domains (e.g., SHBG-like domain) were not mapped","Molecular basis for C4BP and APC interactions remained undefined"]},{"year":1991,"claim":"Detailed biochemical characterization established that the C4BP beta-chain is the sole Protein S binding site, that C4BP complexation abolishes APC cofactor activity, and that calcium binding to EGF-like domains is required for structural integrity, resolving how Protein S bioavailability is regulated.","evidence":"Domain-level binding studies, post-translational modification mapping, cofactor reconstitution assays","pmids":["1833851","1534488"],"confidence":"High","gaps":["Structural basis for how C4BP binding neutralizes APC cofactor function was unknown","In vivo regulation of C4BP beta-chain expression was not addressed"]},{"year":1994,"claim":"Discovery that Protein S directly binds and inhibits Factor Xa and Factor Va and suppresses prothrombinase activity independently of APC revealed a second, autonomous anticoagulant mechanism.","evidence":"Reconstituted binding assays (solid-phase and fluid-phase), FXa amidolytic activity assay, prothrombin conversion assay with purified components","pmids":["8428962","8146182"],"confidence":"High","gaps":["Relative physiological contribution of APC-independent vs APC-dependent anticoagulant activity was unclear","Structural determinants of the Protein S–FXa interaction were not mapped"]},{"year":2002,"claim":"Identification of Protein S as the serum factor that binds phosphatidylserine on apoptotic cells and stimulates macrophage phagocytosis extended its function beyond hemostasis into innate immune clearance.","evidence":"Immunodepletion of Protein S from serum, reconstituted macrophage phagocytosis assay with apoptotic lymphoma cells","pmids":["12447359"],"confidence":"High","gaps":["Receptor on macrophages mediating Protein S-stimulated phagocytosis was not identified","Whether this function operates in vivo and its relationship to autoimmunity was unresolved"]},{"year":2006,"claim":"Protein S was shown to enhance TFPI-mediated inhibition of the tissue factor pathway by reducing the Ki of TFPI for Factor Xa ~10-fold, identifying a third distinct anticoagulant mechanism independent of APC.","evidence":"Purified component coagulation assays, kinetic analysis of FXa inhibition by TFPI ± Protein S","pmids":["16488980"],"confidence":"High","gaps":["Domain of Protein S responsible for TFPI enhancement was not mapped","In vivo significance relative to APC cofactor function was not established"]},{"year":2009,"claim":"Demonstration that gross PROS1 copy number variations account for approximately one-third of mutation-negative hereditary protein S deficiency cases expanded the genetic basis of this thrombophilia beyond point mutations.","evidence":"MLPA and quantitative PCR in hereditary protein S-deficient families","pmids":["19466456"],"confidence":"High","gaps":["Genotype–phenotype correlations for specific CNV types were limited","Prevalence of CNVs across diverse populations was not determined"]},{"year":2013,"claim":"Conditional knockout of Pros1 in T cells revealed that T cell-derived Protein S signals through TAM receptors on dendritic cells to limit DC activation, establishing Protein S as a homeostatic negative feedback ligand bridging adaptive and innate immunity.","evidence":"T cell-specific Pros1 conditional KO mouse, DC activation assays, colitis model, confirmed PROS1 expression in human activated T cells","pmids":["23850380"],"confidence":"High","gaps":["Specific TAM receptor (Mer vs Tyro3 vs Axl) mediating DC suppression was not fully resolved","Downstream signaling cascade in DCs was not defined"]},{"year":2018,"claim":"CRISPR deletion of Pros1 in tumor cells and receptor-KO macrophage studies demonstrated that tumor-secreted Protein S suppresses macrophage M1 polarization via Mer and Tyro3 (not Axl), requiring PTP1b, directly linking Protein S to tumor immune evasion.","evidence":"CRISPR Pros1-KO tumor cells, Mer/Tyro3/Axl-KO and PTP1b-KO macrophages, in vivo tumor models","pmids":["29708510"],"confidence":"High","gaps":["Structural determinants of Protein S selectivity for Mer/Tyro3 over Axl were unknown","Whether pharmacological targeting of Protein S–TAM axis is therapeutically viable was untested"]},{"year":2021,"claim":"Myeloid-specific Pros1 deletion showed that macrophage-derived Protein S suppresses metastatic seeding by restraining pro-inflammatory and pro-tumorigenic cytokine production via MERTK–Socs3/NF-κB signaling, revealing a cell-autonomous immunomodulatory role in the tumor microenvironment.","evidence":"Myeloid-specific Pros1 cKO mouse, lung and breast metastasis models, BMDM conditioned medium assays, MERTK kinase inhibition","pmids":["33848267"],"confidence":"High","gaps":["Relative contribution of myeloid vs tumor-derived PROS1 to net immunosuppression in tumors was not dissected","PROS1-mediated regulation of IL-10, which was MERTK-independent, remains mechanistically unexplained"]},{"year":2022,"claim":"In uveal melanoma, BAP1 loss was shown to epigenetically upregulate PROS1 (via H3K27ac accumulation), and elevated tumor-secreted PROS1 activates MERTK on CD163+ macrophages to promote an immunosuppressive M2 microenvironment, linking epigenetic deregulation to Protein S-mediated immune evasion.","evidence":"ChIP-seq, scRNA-seq, co-culture MERTK phosphorylation assay, siRNA depletion, patient tumor IHC","pmids":["35954340"],"confidence":"High","gaps":["Whether BAP1-driven PROS1 upregulation is generalizable to other BAP1-mutant cancers is unknown","Therapeutic blockade of PROS1–MERTK axis in uveal melanoma has not been tested"]},{"year":null,"claim":"High-resolution structural data for Protein S—including full-length structure, the Protein S–APC interface, and the Protein S–TFPI–FXa ternary complex—remain unavailable, limiting rational drug design and a unified structural understanding of its multi-partner interactions.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length crystal or cryo-EM structure of Protein S","Structural basis of selectivity for Mer/Tyro3 versus Axl as TAM ligand is not resolved","Mechanism by which C4BP binding neutralizes APC cofactor function at the structural level is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,5,7,8,12]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[10,11]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[14,16,17,18,19]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,5,6,12]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,6,10,14,16]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[1,5,7,8,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,14,16,18,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,16,17,18,19]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,15,17]}],"complexes":["Protein S–C4BP complex"],"partners":["C4BPB","TFPI","MERTK","TYRO3","F5","F10","PROC"],"other_free_text":[]},"mechanistic_narrative":"PROS1 encodes Protein S, a vitamin K-dependent plasma glycoprotein that functions as a central anticoagulant regulator and immunomodulatory ligand. As a cofactor for activated protein C (APC), Protein S promotes inactivation of factors Va and VIIIa; it also directly inhibits Factor Xa and prothrombinase independently of APC, and enhances TFPI-mediated suppression of the tissue factor pathway by reducing the Ki of the FXa/TFPI complex approximately 10-fold [PMID:6239102, PMID:8428962, PMID:8146182, PMID:16488980]. Approximately 60% of circulating Protein S is complexed with C4b-binding protein (C4BP), which abrogates its APC cofactor activity; loss-of-function mutations and copy number variations in PROS1 cause hereditary protein S deficiency and recurrent venous thromboembolism [PMID:6454142, PMID:1534488, PMID:19466456]. Beyond hemostasis, Protein S binds phosphatidylserine on apoptotic cells to stimulate macrophage phagocytosis and signals through Mer and Tyro3 TAM receptors to suppress inflammatory cytokine production in dendritic cells and macrophages, thereby restraining innate and adaptive immune activation and modulating tumor immune evasion [PMID:12447359, PMID:23850380, PMID:29708510, PMID:33848267]."},"prefetch_data":{"uniprot":{"accession":"P07225","full_name":"Vitamin K-dependent protein S","aliases":[],"length_aa":676,"mass_kda":75.1,"function":"Anticoagulant plasma protein; it is a cofactor to activated protein C in the degradation of coagulation factors Va and VIIIa. It helps to prevent coagulation and stimulating fibrinolysis","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P07225/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PROS1","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PROS1","total_profiled":1310},"omim":[{"mim_id":"619525","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIw; CDG2W","url":"https://www.omim.org/entry/619525"},{"mim_id":"614514","title":"THROMBOPHILIA DUE TO PROTEIN S DEFICIENCY, AUTOSOMAL RECESSIVE; THPH6","url":"https://www.omim.org/entry/614514"},{"mim_id":"614507","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ir; CDG1R","url":"https://www.omim.org/entry/614507"},{"mim_id":"613878","title":"COAGULATION FACTOR VII; F7","url":"https://www.omim.org/entry/613878"},{"mim_id":"613872","title":"COAGULATION FACTOR X; F10","url":"https://www.omim.org/entry/613872"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"choroid plexus","ntpm":133.4},{"tissue":"liver","ntpm":264.9}],"url":"https://www.proteinatlas.org/search/PROS1"},"hgnc":{"alias_symbol":[],"prev_symbol":["PROS"]},"alphafold":{"accession":"P07225","domains":[{"cath_id":"2.10.25","chopping":"206-242","consensus_level":"medium","plddt":89.1405,"start":206,"end":242},{"cath_id":"2.10.25.10","chopping":"159-200","consensus_level":"medium","plddt":86.9038,"start":159,"end":200},{"cath_id":"2.10.25.10","chopping":"245-283","consensus_level":"medium","plddt":91.1638,"start":245,"end":283},{"cath_id":"2.60.120.200","chopping":"295-477","consensus_level":"high","plddt":87.4566,"start":295,"end":477},{"cath_id":"2.60.120.200","chopping":"483-666","consensus_level":"high","plddt":88.2542,"start":483,"end":666}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P07225","model_url":"https://alphafold.ebi.ac.uk/files/AF-P07225-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P07225-F1-predicted_aligned_error_v6.png","plddt_mean":82.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PROS1","jax_strain_url":"https://www.jax.org/strain/search?query=PROS1"},"sequence":{"accession":"P07225","fasta_url":"https://rest.uniprot.org/uniprotkb/P07225.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P07225/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P07225"}},"corpus_meta":[{"pmid":"18457993","id":"PMC_18457993","title":"The proPO-system: pros and cons for its role in invertebrate immunity.","date":"2008","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18457993","citation_count":804,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25557259","id":"PMC_25557259","title":"PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.","date":"2014","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25557259","citation_count":423,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20347861","id":"PMC_20347861","title":"The pros and cons of phytoestrogens.","date":"2010","source":"Frontiers in neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/20347861","citation_count":417,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31018669","id":"PMC_31018669","title":"The Pros and Cons of Mesenchymal Stem Cell-Based Therapies.","date":"2019","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/31018669","citation_count":386,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35392976","id":"PMC_35392976","title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.","date":"2022","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/35392976","citation_count":377,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17185269","id":"PMC_17185269","title":"Nanoparticles: health effects--pros and cons.","date":"2006","source":"Environmental health perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/17185269","citation_count":293,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33412697","id":"PMC_33412697","title":"Adding Molecules to Food, Pros and Cons: A Review on Synthetic and Natural Food Additives.","date":"2014","source":"Comprehensive reviews in food science and food safety","url":"https://pubmed.ncbi.nlm.nih.gov/33412697","citation_count":270,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28948500","id":"PMC_28948500","title":"Blocking CGRP in migraine patients - a review of pros and cons.","date":"2017","source":"The journal of headache and pain","url":"https://pubmed.ncbi.nlm.nih.gov/28948500","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19059901","id":"PMC_19059901","title":"Are tests of sperm DNA damage clinically useful? Pros and cons.","date":"2008","source":"Journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/19059901","citation_count":197,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26778084","id":"PMC_26778084","title":"From in vitro Experiments to in vivo and Clinical Studies; Pros and Cons.","date":"2015","source":"Current drug discovery technologies","url":"https://pubmed.ncbi.nlm.nih.gov/26778084","citation_count":191,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29708510","id":"PMC_29708510","title":"Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29708510","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29292104","id":"PMC_29292104","title":"Statins: pros and cons.","date":"2017","source":"Medicina clinica","url":"https://pubmed.ncbi.nlm.nih.gov/29292104","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29534892","id":"PMC_29534892","title":"Pros and cons of different therapeutic antibody formats for recombinant antivenom development.","date":"2018","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/29534892","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30965277","id":"PMC_30965277","title":"Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/30965277","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16501583","id":"PMC_16501583","title":"Cannabinoids and cancer: pros and cons of an antitumour strategy.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16501583","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33859650","id":"PMC_33859650","title":"Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33859650","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12533214","id":"PMC_12533214","title":"The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs.","date":"2002","source":"Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada","url":"https://pubmed.ncbi.nlm.nih.gov/12533214","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26980434","id":"PMC_26980434","title":"Maillard reaction in food allergy: Pros and cons.","date":"2017","source":"Critical reviews in food science and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/26980434","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24337808","id":"PMC_24337808","title":"Lysosomal multienzyme complex: pros and cons of working together.","date":"2013","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/24337808","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25936606","id":"PMC_25936606","title":"The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies.","date":"2015","source":"Progress in retinal and eye research","url":"https://pubmed.ncbi.nlm.nih.gov/25936606","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27426476","id":"PMC_27426476","title":"CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).","date":"2016","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27426476","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27715478","id":"PMC_27715478","title":"In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies.","date":"2016","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/27715478","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30447707","id":"PMC_30447707","title":"The Properties of Cytokines in Multiple Sclerosis: Pros and Cons.","date":"2018","source":"The American journal of the medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30447707","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31699565","id":"PMC_31699565","title":"Pros and Cons of Chaperone-Mediated Autophagy in Cancer Biology.","date":"2019","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/31699565","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11086331","id":"PMC_11086331","title":"Pros and cons of inhibiting cholesteryl ester transfer protein.","date":"2000","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/11086331","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20153401","id":"PMC_20153401","title":"Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20153401","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32478071","id":"PMC_32478071","title":"Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32478071","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26194026","id":"PMC_26194026","title":"Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.","date":"2015","source":"Intensive care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26194026","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33848267","id":"PMC_33848267","title":"Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33848267","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27516729","id":"PMC_27516729","title":"Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons.","date":"2016","source":"Current colorectal cancer reports","url":"https://pubmed.ncbi.nlm.nih.gov/27516729","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26049635","id":"PMC_26049635","title":"Heat shock proteins and heat therapy for type 2 diabetes: pros and cons.","date":"2015","source":"Current opinion in clinical nutrition and metabolic care","url":"https://pubmed.ncbi.nlm.nih.gov/26049635","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24377908","id":"PMC_24377908","title":"The pros and the cons of mTOR inhibitors in kidney transplantation.","date":"2013","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24377908","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33219449","id":"PMC_33219449","title":"Current methods for diagnosis of human coronaviruses: pros and cons.","date":"2020","source":"Analytical and bioanalytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33219449","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16684219","id":"PMC_16684219","title":"Bioartificial liver: its pros and cons.","date":"2006","source":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16684219","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37508559","id":"PMC_37508559","title":"Revisiting Two Decades of Research Focused on Targeting APE1 for Cancer Therapy: The Pros and Cons.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37508559","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12650712","id":"PMC_12650712","title":"Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments.","date":"2002","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12650712","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31440506","id":"PMC_31440506","title":"Models of Intracellular Transport: Pros and Cons.","date":"2019","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31440506","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26583156","id":"PMC_26583156","title":"Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.","date":"2015","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/26583156","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32416986","id":"PMC_32416986","title":"Wnt/β-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons.","date":"2020","source":"Clinical breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32416986","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31709192","id":"PMC_31709192","title":"The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31709192","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22725618","id":"PMC_22725618","title":"Pregabalin in clinical psychiatry and addiction: pros and cons.","date":"2012","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/22725618","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35819853","id":"PMC_35819853","title":"Liver-on-a-chip devices: the pros and cons of complexity.","date":"2022","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35819853","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24923569","id":"PMC_24923569","title":"Pros and cons of current approaches for detecting peroxynitrite and their applications.","date":"2014","source":"Biomedical journal","url":"https://pubmed.ncbi.nlm.nih.gov/24923569","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24637706","id":"PMC_24637706","title":"Downstream processing of biopharmaceutical proteins produced in plants: the pros and cons of flocculants.","date":"2014","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/24637706","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27411319","id":"PMC_27411319","title":"Pros and Cons of Clinical Basophil Testing (BAT).","date":"2016","source":"Current allergy and asthma reports","url":"https://pubmed.ncbi.nlm.nih.gov/27411319","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19466456","id":"PMC_19466456","title":"Gross deletions/duplications in PROS1 are relatively common in point mutation-negative hereditary protein S deficiency.","date":"2009","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19466456","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35954340","id":"PMC_35954340","title":"BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35954340","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26134828","id":"PMC_26134828","title":"Pros and cons of methylation-based enrichment methods for ancient DNA.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26134828","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25835096","id":"PMC_25835096","title":"Pros and cons of fatty acids in bone biology.","date":"2015","source":"Progress in lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25835096","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25430061","id":"PMC_25430061","title":"Scrambling free combinatorial labeling of alanine-β, isoleucine-δ1, leucine-proS and valine-proS methyl groups for the detection of long range NOEs.","date":"2014","source":"Journal of biomolecular NMR","url":"https://pubmed.ncbi.nlm.nih.gov/25430061","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19885254","id":"PMC_19885254","title":"Insulin delivery route for the artificial pancreas: subcutaneous, intraperitoneal, or intravenous? Pros and cons.","date":"2008","source":"Journal of diabetes science and technology","url":"https://pubmed.ncbi.nlm.nih.gov/19885254","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27840905","id":"PMC_27840905","title":"Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27840905","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35262966","id":"PMC_35262966","title":"Pros and cons of causative association between periodontitis and rheumatoid arthritis.","date":"2022","source":"Periodontology 2000","url":"https://pubmed.ncbi.nlm.nih.gov/35262966","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28685694","id":"PMC_28685694","title":"Multi-targeting Strategies for Alzheimer's Disease Therapeutics: Pros and Cons.","date":"2017","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28685694","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31766614","id":"PMC_31766614","title":"Tumour-Secreted Protein S (ProS1) Activates a Tyro3-Erk Signalling Axis and Protects Cancer Cells from Apoptosis.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31766614","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21863500","id":"PMC_21863500","title":"Noise in biological systems: pros, cons, and mechanisms of control.","date":"2011","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/21863500","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25601468","id":"PMC_25601468","title":"Emerging role for αB-crystallin as a therapeutic agent: pros and cons.","date":"2015","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25601468","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28361440","id":"PMC_28361440","title":"Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.","date":"2017","source":"Clinical drug investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28361440","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29975952","id":"PMC_29975952","title":"Pros and Cons of the New Edition of TNM Classification of Head and Neck Squamous Cell Carcinoma.","date":"2018","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29975952","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33861488","id":"PMC_33861488","title":"Urea-Urease Reaction in Controlling Properties of Supramolecular Hydrogels: Pros and Cons.","date":"2021","source":"Chemistry (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/33861488","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37841752","id":"PMC_37841752","title":"CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review.","date":"2023","source":"Therapeutic advances in medical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37841752","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22318610","id":"PMC_22318610","title":"Is EPCR a multi-ligand receptor? Pros and cons.","date":"2012","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/22318610","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29343255","id":"PMC_29343255","title":"Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise.","date":"2018","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/29343255","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18227473","id":"PMC_18227473","title":"Treatment of type 2 diabetes with combined therapy: what are the pros and cons?","date":"2008","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/18227473","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38175415","id":"PMC_38175415","title":"Pros and Cons in Various Immobilization Techniques and Carriers for Enzymes.","date":"2024","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38175415","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36362032","id":"PMC_36362032","title":"Pros and Cons of In Vitro Methods for Circular RNA Preparation.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36362032","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33359376","id":"PMC_33359376","title":"HtrA family proteases of bacterial pathogens: pros and cons for their therapeutic use.","date":"2021","source":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33359376","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24476362","id":"PMC_24476362","title":"Multipotent (adult) and pluripotent stem cells for heart regeneration: what are the pros and cons?","date":"2013","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24476362","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28577738","id":"PMC_28577738","title":"[PIK3CA-related overgrowth syndrome (PROS)].","date":"2017","source":"Nephrologie & therapeutique","url":"https://pubmed.ncbi.nlm.nih.gov/28577738","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28091967","id":"PMC_28091967","title":"Balancing Ethical Pros and Cons of Stem Cell Derived Gametes.","date":"2017","source":"Annals of biomedical engineering","url":"https://pubmed.ncbi.nlm.nih.gov/28091967","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26680098","id":"PMC_26680098","title":"Pros and cons of pDNA and mRNA transfection to study mRNA translation in mammalian cells.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26680098","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26812876","id":"PMC_26812876","title":"Measurement of free light chains - pros and cons of current methods.","date":"2016","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26812876","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33015196","id":"PMC_33015196","title":"Inflammation and Inflammasomes: Pros and Cons in Tumorigenesis.","date":"2020","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/33015196","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11237072","id":"PMC_11237072","title":"Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation.","date":"2001","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/11237072","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34587557","id":"PMC_34587557","title":"Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy.","date":"2021","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/34587557","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28937838","id":"PMC_28937838","title":"Protein Supplements: Pros and Cons.","date":"2017","source":"Journal of dietary supplements","url":"https://pubmed.ncbi.nlm.nih.gov/28937838","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37849741","id":"PMC_37849741","title":"New insights in application of mesenchymal stem cells therapy in tumor microenvironment: pros and cons.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/37849741","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35407379","id":"PMC_35407379","title":"Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35407379","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6410914","id":"PMC_6410914","title":"Antigen detection in cerebrospinal fluid--pros and cons.","date":"1983","source":"The American journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6410914","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37643501","id":"PMC_37643501","title":"ProS-GNN: Predicting effects of mutations on protein stability using graph neural networks.","date":"2023","source":"Computational biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37643501","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27249750","id":"PMC_27249750","title":"Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.","date":"2016","source":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","url":"https://pubmed.ncbi.nlm.nih.gov/27249750","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35124195","id":"PMC_35124195","title":"Extracellular vesicles in cancer pros and cons: The importance of the evidence-based medicine.","date":"2022","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/35124195","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35116109","id":"PMC_35116109","title":"Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons.","date":"2022","source":"World journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35116109","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11776305","id":"PMC_11776305","title":"Characterization and structural impact of five novel PROS1 mutations in eleven protein S-deficient families.","date":"2001","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11776305","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17437683","id":"PMC_17437683","title":"Leukotriene synthesis inhibitors versus antagonists: the pros and cons.","date":"2007","source":"Current allergy and asthma reports","url":"https://pubmed.ncbi.nlm.nih.gov/17437683","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31581722","id":"PMC_31581722","title":"The Pros and Cons of Using Oat in a Gluten-Free Diet for Celiac Patients.","date":"2019","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/31581722","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30303861","id":"PMC_30303861","title":"Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions.","date":"2018","source":"Journal of clinical psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30303861","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33015057","id":"PMC_33015057","title":"In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33015057","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34283001","id":"PMC_34283001","title":"Early approval of COVID-19 vaccines: Pros and cons.","date":"2021","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34283001","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8941500","id":"PMC_8941500","title":"Oral vs inhaled asthma therapy. Pros, cons and combinations.","date":"1996","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/8941500","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38365828","id":"PMC_38365828","title":"Administration of methylene blue in septic shock: pros and cons.","date":"2024","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38365828","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39327187","id":"PMC_39327187","title":"Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions.","date":"2024","source":"European urology oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39327187","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32964666","id":"PMC_32964666","title":"Recurrent PROC and novel PROS1 mutations in Vietnamese patients diagnosed with idiopathic deep venous thrombosis.","date":"2020","source":"International journal of laboratory hematology","url":"https://pubmed.ncbi.nlm.nih.gov/32964666","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35008687","id":"PMC_35008687","title":"Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35008687","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36213308","id":"PMC_36213308","title":"Unraveling the pros and cons of various in vitro methodologies for ruminant nutrition: a review.","date":"2022","source":"Translational animal science","url":"https://pubmed.ncbi.nlm.nih.gov/36213308","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32775356","id":"PMC_32775356","title":"Pros and Cons of Robotic Revisional Bariatric Surgery.","date":"2020","source":"Visceral medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32775356","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22912543","id":"PMC_22912543","title":"B cell depletion in treating primary biliary cirrhosis: pros and cons.","date":"2012","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/22912543","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36641897","id":"PMC_36641897","title":"EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.","date":"2022","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/36641897","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32998409","id":"PMC_32998409","title":"Electrochemical Immuno- and Aptamer-Based Assays for Bacteria: Pros and Cons over Traditional Detection Schemes.","date":"2020","source":"Sensors (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32998409","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31165154","id":"PMC_31165154","title":"The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.","date":"2019","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/31165154","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14630798","id":"PMC_14630798","title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14630798","citation_count":616,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6239102","id":"PMC_6239102","title":"Recurrent venous thromboembolism in patients with a partial deficiency of protein S.","date":"1984","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6239102","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26871637","id":"PMC_26871637","title":"Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26871637","citation_count":423,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6454142","id":"PMC_6454142","title":"High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein.","date":"1981","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6454142","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2952034","id":"PMC_2952034","title":"Hereditary protein S deficiency: clinical manifestations.","date":"1987","source":"Annals of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2952034","citation_count":372,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12447359","id":"PMC_12447359","title":"Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12447359","citation_count":336,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1833851","id":"PMC_1833851","title":"Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system.","date":"1991","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/1833851","citation_count":330,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16488980","id":"PMC_16488980","title":"Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16488980","citation_count":261,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14607961","id":"PMC_14607961","title":"Inhibition of fibrocyte differentiation by serum amyloid P.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14607961","citation_count":252,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8428962","id":"PMC_8428962","title":"Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8428962","citation_count":211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2944113","id":"PMC_2944113","title":"Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2944113","citation_count":202,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8146182","id":"PMC_8146182","title":"Protein S binds to and inhibits factor Xa.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8146182","citation_count":160,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12907438","id":"PMC_12907438","title":"Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12907438","citation_count":155,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23850380","id":"PMC_23850380","title":"T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response.","date":"2013","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23850380","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2148110","id":"PMC_2148110","title":"Organization of the human protein S genes.","date":"1990","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2148110","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2940598","id":"PMC_2940598","title":"Primary structure of bovine vitamin K-dependent protein S.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2940598","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23533145","id":"PMC_23533145","title":"In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.","date":"2013","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23533145","citation_count":138,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1534488","id":"PMC_1534488","title":"Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin.","date":"1992","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1534488","citation_count":129,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38679,"output_tokens":2269,"usd":0.075036},"stage2":{"model":"claude-opus-4-6","input_tokens":5543,"output_tokens":2301,"usd":0.12786},"total_usd":0.509782,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":51496,"output_tokens":5244,"usd":0.116574},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9030,"output_tokens":3269,"usd":0.190312}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"Tumor-secreted Protein S (PROS1) acts as a ligand for Mer and Tyro3 (but not Axl) receptor tyrosine kinases on macrophages, suppressing M1 macrophage polarization and cytokine expression (IFN-γ and LPS-induced). The suppressive pathway involves PTP1b complexing with Mer downstream of PROS1/TAM activation. CRISPR-based deletion of Pros1 in tumor cells abrogated M1 cytokine suppression, and this suppression was lost in macrophages from Mer-KO, Tyro3-KO, and PTP1b-KO mice.\",\n      \"method\": \"CRISPR-based gene deletion, cytokine assays, macrophage KO mice (Mer, Tyro3, Axl, PTP1b), co-IP (PTP1b-Mer complex), in vivo tumor models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal KO models, genetic deletion, pathway dissection with PTP1b co-complex, in vivo validation\",\n      \"pmids\": [\"29708510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tumor-secreted PROS1 (ProS1) functions as a functional ligand for Tyro3 receptor tyrosine kinase in cancer cells, preferentially activating Tyro3 and downstream Erk kinase phosphorylation more potently than Gas6. In cells expressing both Tyro3 and Axl, Gas6 exclusively activated Axl/Akt, while ProS1 was the dominant Tyro3/Erk activator. ProS1-Tyro3-Erk signaling protected cancer cells from staurosporine-induced apoptosis and serum starvation-induced apoptosis.\",\n      \"method\": \"Western blotting (kinase phosphorylation), conditioned medium experiments, ProS1 ligand traps, warfarin treatment, apoptosis assays in cancer cell lines with differential TAM receptor expression\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell lines, ligand traps and warfarin as specificity controls, apoptosis functional readout; single lab\",\n      \"pmids\": [\"31766614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Myeloid cell-derived PROS1 suppresses metastasis via MERTK signaling in macrophages. PROS1 deletion in myeloid cells elevated TNF-α, IL-6, Nos2, and IL-10 via the Socs3/NF-κB pathway. Conditioned medium from PROS1-cKO bone marrow-derived macrophages enhanced EMT, ERK, AKT, and STAT3 activation in tumor cells and promoted IL-10-dependent invasion. Inhibition of MERTK kinase activity blocked PROS1-mediated suppression of TNF-α and IL-6 but not IL-10, revealing divergent downstream signaling.\",\n      \"method\": \"Conditional myeloid-specific Pros1 knockout mice, BMDM conditioned medium experiments, MERTK kinase inhibition, cytokine assays, tumor metastasis models (lung, breast), T cell proliferation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO in vivo, mechanistic dissection of MERTK/Socs3/NF-κB pathway, multiple orthogonal functional assays, two tumor models\",\n      \"pmids\": [\"33848267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BAP1 loss in uveal melanoma cells epigenetically upregulates PROS1 expression via accumulation of H3K27ac at the PROS1 locus (identified by ChIP-seq). Secreted PROS1 from BAP1-deficient cells phosphorylates and activates the immunosuppressive macrophage receptor MERTK; depletion of PROS1 in BAP1-KO cells blocked MERTK phosphorylation in co-cultured macrophages, establishing a mechanistic link between BAP1 loss and immune suppression via the PROS1-MERTK axis.\",\n      \"method\": \"ChIP-seq (H3K27ac), RNA-seq, PROS1 depletion (siRNA/CRISPR), co-culture with RAW 264.7 macrophages, MERTK phosphorylation assay, multicolor immunohistochemistry\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP-seq for epigenetic mechanism, functional rescue by PROS1 depletion, MERTK phosphorylation readout, validated in patient tissue\",\n      \"pmids\": [\"35954340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Knockdown of PROS1 in glioblastoma cells (LN18) induced apoptosis via activation of both extrinsic and intrinsic apoptotic pathways, with major upregulation of FasL (death receptor signaling) and downregulation of GAS6 and TAM family receptors. PROS1 silencing also significantly reduced cell migration, invasion (by ~82%), and proliferation, placing PROS1 upstream of TAM receptor signaling in GBM cell survival.\",\n      \"method\": \"siRNA knockdown, apoptosis assays, wound-healing assay, invasion assay, proliferation assay, expression analysis of FasL, GAS6, TAM receptors\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — clean KD with defined cellular phenotypes and pathway readouts (FasL, GAS6, TAM receptors), single lab, single cell line\",\n      \"pmids\": [\"27840905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Five novel PROS1 mutations (W108C, W342R, E349K, L485S missense mutations and a 4 bp deletion causing frameshift) were identified in protein S-deficient families. Platelet mRNA analysis showed mutant transcripts were expressed, but structural modeling predicted defective protein folding/stability. The primary molecular disease mechanism for these missense mutations is impaired secretion and intracellular degradation of misfolded PROS1 protein, not absent transcription.\",\n      \"method\": \"DNA sequencing, mRNA analysis from platelets, haplotype analysis (microsatellite markers), computational structural modeling of protein S\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3-4 — mRNA expression confirmed but mechanism of protein misfolding inferred from computational modeling without in vitro reconstitution\",\n      \"pmids\": [\"11776305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Gross copy number variations (complete deletions, partial deletions, and duplications) of the PROS1 gene account for hereditary protein S deficiency in approximately one-third of point mutation-negative cases, as detected by MLPA and confirmed by quantitative PCR.\",\n      \"method\": \"Multiplex ligation-dependent probe amplification (MLPA), quantitative PCR (qPCR), family segregation analysis\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal molecular detection methods (MLPA + qPCR), confirmed in multiple families; establishes genomic mechanism of PROS1 deficiency\",\n      \"pmids\": [\"19466456\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PROS1 (Protein S) is a secreted ligand for TAM receptor tyrosine kinases (primarily Mer/MERTK and Tyro3, not Axl) that activates downstream Erk and, context-dependently, Akt signaling; in macrophages, tumor-secreted PROS1 drives immunosuppression by engaging Mer/Tyro3 to recruit PTP1b and suppress M1 cytokine production via Socs3/NF-κB, while myeloid-derived PROS1 conversely limits metastasis through MERTK-dependent regulation of IL-10; in cancer cells, autocrine/paracrine PROS1-Tyro3-Erk signaling promotes cell survival and invasiveness, and PROS1 expression is epigenetically upregulated by BAP1 loss via H3K27ac accumulation at the PROS1 locus.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1981,\n      \"finding\": \"Protein S (encoded by PROS1) exists in two forms in plasma: free protein and in a high-molecular-weight complex with complement component C4b-binding protein (C4BP), held together by noncovalent bonds; a major proportion of C4BP in plasma is complexed with protein S, establishing that protein S is a binding partner for C4BP.\",\n      \"method\": \"Barium citrate adsorption, SDS-PAGE with and without reduction, biochemical fractionation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original biochemical reconstitution and fractionation, foundational paper replicated extensively\",\n      \"pmids\": [\"6454142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1984,\n      \"finding\": \"Protein S functions as a cofactor for activated protein C (APC), which inhibits blood clotting at the levels of factors V and VIII; deficiency of protein S leads to inadequate anticoagulant regulation and recurrent venous thromboembolism, establishing protein S's essential role in the protein C anticoagulant pathway.\",\n      \"method\": \"Functional assay for protein S activity in plasma, clinical phenotype in protein S-deficient patients\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional assay with defined cellular/biochemical phenotype, foundational paper widely replicated\",\n      \"pmids\": [\"6239102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Human protein S is a single-chain 635-amino-acid vitamin K-dependent plasma protein with an N-terminal Gla domain, a thrombin-sensitive region, four EGF-like repeat domains, and a C-terminal region homologous to androgen-binding proteins/SHBG; it is structurally distinct from other vitamin K-dependent coagulation proteins in lacking a serine protease domain.\",\n      \"method\": \"cDNA cloning and sequencing of human liver cDNA library, comparison to bovine protein S sequence\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — primary sequence determination by cDNA cloning, foundational structural paper\",\n      \"pmids\": [\"2944113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Bovine protein S primary structure confirmed by cDNA sequencing and protein sequencing: single polypeptide of 634 amino acids, one asparagine-linked carbohydrate, a Gla domain, thrombin-sensitive region (residues 42–75), four EGF-like cysteine-rich repeats, and a C-terminal SHBG-homologous domain; cofactor function for activated protein C in inactivation of coagulation factors Va and VIIIa established.\",\n      \"method\": \"Full-length cDNA sequencing from bovine liver library and direct protein sequencing (95% coverage)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted structural and sequence data with protein sequencing validation\",\n      \"pmids\": [\"2940598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The human protein S expressed gene (PROS1/PS-alpha) spans >80 kb with 15 exons and 14 introns; exons I–VIII encode the vitamin K-dependent module (Gla domain, EGF-like repeats) with intron positions identical to other vitamin K-dependent coagulation proteins, while exons IX–XV encode the SHBG-homologous domain with identical intron positions as the SHBG gene, revealing its mosaic evolutionary origin. A pseudogene (PS-beta) with 97% coding identity but multiple frameshifts/stop codons was also characterized.\",\n      \"method\": \"Genomic clone isolation, restriction mapping, exon–intron sequencing, comparative genomic analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct genomic sequencing and structural characterization\",\n      \"pmids\": [\"2148110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Protein S acts as a cofactor for activated protein C (APC) in the degradation of phospholipid-bound coagulation factors Va and VIIIa; protein S contains post-translational modifications including 11 Gla residues, beta-hydroxylated Asp in EGF1 and beta-hydroxylated Asn in EGF2–4; calcium binds with high affinity to EGF-like domains playing a structural/stabilizing role; the C4BP-complexed form of protein S lacks APC cofactor function; C4BP beta-chain contains the single protein S binding site.\",\n      \"method\": \"Protein biochemistry, domain characterization, complex reconstitution, cofactor activity assays\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biochemical assays, domain mapping of post-translational modifications and binding sites\",\n      \"pmids\": [\"1833851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"In plasma, free protein S (~38% of total, ~131 nmol/L) and C4BP-bound protein S (~62%) coexist in a 1:1 molar stoichiometry with C4BP beta-chain; free C4BP predominantly lacks the beta-chain; plasma levels of C4BP beta-chain directly and stoichiometrically regulate free protein S levels; free protein S antigen correlates with protein S anticoagulant activity.\",\n      \"method\": \"Immunoadsorption with anti-C4BP and anti-protein S antibody-Sepharose columns, ELISA quantitation in human plasma samples\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — quantitative immunoadsorption and ELISA, stoichiometric binding demonstrated\",\n      \"pmids\": [\"1534488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Protein S directly binds to Factor Va in a calcium-dependent, saturable, and reversible manner (Kd ~33 nM in fluid phase); protein S competes with prothrombin for binding to Factor Va; protein S inhibits prothrombinase activity independently of activated protein C, by a mixed inhibition mechanism, with ~50% inhibition at ~16 nM protein S.\",\n      \"method\": \"Solid-phase binding assay (immobilized factor Va/protein S), fluid-phase binding with biotin-labeled factors, prothrombinase activity assay with purified clotting factors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro binding and functional assay, multiple orthogonal methods\",\n      \"pmids\": [\"8428962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Protein S directly binds to Factor Xa (Kd ~18–19 nM), inhibits Factor Xa amidolytic activity (~50% at 33 nM), and inhibits prothrombin conversion to thrombin by Factor Xa in a phospholipid-independent, Ca2+-stimulated manner; these anticoagulant mechanisms are independent of activated protein C and involve direct interactions with both Factor Xa and Factor Va.\",\n      \"method\": \"Ligand blotting, solid-phase and fluid-phase binding assays, factor Xa amidolytic activity assay, prothrombin conversion assay, one-stage clotting assay in protein S-depleted plasma\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple in vitro reconstituted assays with purified components, replicated binding by multiple methods\",\n      \"pmids\": [\"8146182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Four novel PROS1 missense mutations (W108C, W342R, E349K, L485S) and one 4-bp deletion causing frameshift in codons 632–633 cause Type I or III protein S deficiency; platelet mRNA analysis showed mutant transcripts are expressed, suggesting the primary molecular mechanism is defective protein folding/instability and impaired secretion with intracellular degradation, rather than absence of mRNA.\",\n      \"method\": \"DNA sequencing of PROS1, haplotype analysis with microsatellite markers, platelet mRNA analysis, computer-based structural modeling of protein S\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — mRNA expression analysis plus structural modeling, single lab but multiple methodological approaches\",\n      \"pmids\": [\"11776305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Protein S binds to phosphatidylserine (PS) exposed on the surface of apoptotic cells and stimulates macrophage phagocytosis of apoptotic cells; immunodepletion of protein S from serum eliminated the pro-phagocytic activity of serum, identifying protein S as the serum factor responsible for serum-enhanced clearance of apoptotic cells.\",\n      \"method\": \"Protein purification from serum, immunodepletion of protein S, macrophage phagocytosis assay with apoptotic lymphoma cells, phosphatidylserine binding assay\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — purified protein functional reconstitution, immunodepletion confirmation, multiple assays\",\n      \"pmids\": [\"12447359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Protein S circulates ~40% as free PS and ~60% complexed with C4BP; the PS–C4BP complex binds to apoptotic cells, positioning C4BP as a bridge between coagulation and complement regulation; complexed protein S loses APC cofactor function while C4BP modulates APC anticoagulant activity.\",\n      \"method\": \"Review/synthesis of biochemical binding studies, complement activation assays, apoptotic cell binding experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesis of experimental evidence from multiple studies\",\n      \"pmids\": [\"12907438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Protein S specifically stimulates inhibition of the tissue factor (TF) pathway by promoting the interaction between full-length TF pathway inhibitor (TFPI) and Factor Xa (FXa); protein S causes a 10-fold reduction in the Ki of the FXa/TFPI complex (from 4.4 nM to 0.5 nM), accelerating feedback inhibition of the TF-mediated coagulation pathway and acting in concert with TFPI independently of activated protein C.\",\n      \"method\": \"Purified component in vitro coagulation assays, kinetic analysis of FXa inhibition by TFPI in presence/absence of protein S, thrombin generation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro assay with purified proteins, kinetic parameters determined\",\n      \"pmids\": [\"16488980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Gross copy number variations (CNVs) in PROS1—including complete gene deletions, partial deletions (exons 4–9 or 9–11), and partial duplications—account for protein S deficiency in approximately one-third of point mutation-negative hereditary PS-deficient patients, identified by MLPA and confirmed by quantitative PCR.\",\n      \"method\": \"Multiplex ligation-dependent probe amplification (MLPA), quantitative PCR confirmation, family member testing\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal CNV detection methods, multiple independent probands\",\n      \"pmids\": [\"19466456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"T cell-derived Protein S (Pros1) signals through TAM receptor tyrosine kinases (specifically on dendritic cells) to limit the magnitude of DC activation; genetic ablation of Pros1 in mouse T cells increased expression of costimulatory molecules and cytokines in DCs, enhanced immune responses to T cell-dependent antigens, and increased colitis severity, revealing a homeostatic negative feedback mechanism between adaptive and innate immunity.\",\n      \"method\": \"Conditional Pros1 knockout in T cells (mouse), DC activation assays, cytokine measurement, colitis model, human PROS1 expression in activated T cells confirmed\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined cellular phenotype, multiple immune readouts, human relevance confirmed\",\n      \"pmids\": [\"23850380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PROS1 knockdown in LN18 glioblastoma cells (siRNA) induces apoptosis via activation of both extrinsic (FasL/death receptor) and intrinsic apoptotic pathways, reduces migration and invasion (by up to 82%), and reduces proliferation; PROS1 silencing also downregulates GAS6 and other TAM family receptors, suggesting PROS1 promotes GBM cell survival through the TAM signaling axis.\",\n      \"method\": \"siRNA knockdown in LN18 GBM cells, apoptosis assays, wound-healing assay, invasion assay, proliferation assay, expression analysis\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — siRNA loss-of-function with multiple functional readouts, single lab\",\n      \"pmids\": [\"27840905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Tumor-secreted Protein S (Pros1) inhibits macrophage M1 polarization (suppressing IFN-γ/LPS-induced M1 cytokine expression) via Mer and Tyro3 (but not Axl) TAM receptors; this suppressive action requires PTP1b complexing with Mer; CRISPR deletion of Pros1 in tumor cells abrogated M1 suppression; IFN-γ induces Pros1 transcription and secretion in tumor cells; Pros1-deficient tumors showed increased innate and adaptive immune infiltration and improved survival in mice.\",\n      \"method\": \"CRISPR-based Pros1 deletion in tumor cells, Mer/Tyro3/Axl-KO macrophages, PTP1b-KO macrophages, in vitro M1 polarization assay, in vivo tumor survival experiments, cytokine measurement\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic KO models (CRISPR, receptor KO, PTP1b KO), in vitro and in vivo, orthogonal approaches\",\n      \"pmids\": [\"29708510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tumor-secreted ProS1 activates Tyro3 and stimulates Erk phosphorylation more potently than Gas6; in cells expressing Tyro3 alone (MGH-U3), ProS1 additionally activates Akt; Gas6 is the sole stimulator of Axl and Akt in cells co-expressing Axl; ProS1 protects cancer cells from staurosporine-induced and serum starvation-induced apoptosis through Tyro3–Erk (and Akt where Tyro3 is sole TAM receptor) signaling.\",\n      \"method\": \"Western blotting of kinase phosphorylation, conditioned medium experiments, ProS1 ligand traps and warfarin specificity controls, apoptosis assays in multiple cancer cell lines\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple cell lines and ligand specificity controls, but single lab\",\n      \"pmids\": [\"31766614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Myeloid cell-derived PROS1 suppresses metastatic seeding in lung and breast cancer models; PROS1 deletion in myeloid cells (cKO) elevated TNF-α, IL-6, Nos2, and IL-10 via modulation of Socs3/NF-κB; cKO BMDM conditioned medium enhanced EMT and activated ERK, AKT, and STAT3 in tumor cells promoting IL-10-dependent invasion; MERTK kinase activity mediates PROS1 suppression of TNF-α and IL-6 but not IL-10; PROS1/MERTK axis in macrophages modulates T cell proliferation and DC costimulatory molecule expression.\",\n      \"method\": \"Myeloid-specific Pros1 conditional knockout mouse, BMDM conditioned medium experiments, lung and breast metastasis models, cytokine and signaling pathway analysis, MERTK kinase inhibition\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific genetic KO with in vivo metastasis phenotype, multiple orthogonal mechanistic analyses\",\n      \"pmids\": [\"33848267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BAP1 loss in uveal melanoma leads to epigenetic upregulation of PROS1 (accumulation of H3K27ac at the PROS1 locus per ChIP-seq); elevated tumor-secreted PROS1 activates MERTK (increased phosphorylation) in CD163+ macrophages, promoting an immunosuppressive M2-polarized tumor microenvironment; PROS1 depletion in BAP1-/- uveal melanocytes blocked MERTK phosphorylation in co-cultured macrophages.\",\n      \"method\": \"ChIP-seq (H3K27ac), RNA-seq and single-cell RNA-seq, co-culture MERTK phosphorylation assay, siRNA PROS1 depletion, multicolor immunohistochemistry on patient tumors\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP-seq, scRNA-seq, functional co-culture, IHC), mechanistic link established\",\n      \"pmids\": [\"35954340\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PROS1 (Protein S) is a multifunctional vitamin K-dependent plasma glycoprotein with a Gla domain, thrombin-sensitive region, four EGF-like domains, and an SHBG-homologous C-terminal domain; it acts as an anticoagulant cofactor for activated protein C (facilitating degradation of factors Va and VIIIa), directly inhibits Factor Xa and prothrombinase independently of APC, enhances TFPI-mediated suppression of the tissue factor pathway, circulates ~40% free and ~60% in complex with C4BP (which abrogates its APC cofactor function), binds phosphatidylserine on apoptotic cells to stimulate macrophage phagocytic clearance, and signals through TAM receptor tyrosine kinases (Mer, Tyro3) on immune cells (dendritic cells, macrophages) to suppress inflammatory cytokine production and modulate innate and adaptive immune responses, including restraining tumor-associated macrophage M1 polarization and metastasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PROS1 (Protein S) is a secreted ligand for TAM family receptor tyrosine kinases — specifically MERTK and Tyro3, but not Axl — that functions as a central mediator of immune regulation and cancer cell survival. Tumor-secreted PROS1 engages Mer and Tyro3 on macrophages to suppress M1 polarization and pro-inflammatory cytokine production through recruitment of PTP1b to the Mer receptor complex, while myeloid-derived PROS1 limits metastasis by restraining TNF-α, IL-6, and IL-10 via a MERTK-dependent Socs3/NF-κB pathway [PMID:29708510, PMID:33848267]. In cancer cells, PROS1 preferentially activates Tyro3 and downstream Erk signaling to promote survival and invasiveness, and its expression is epigenetically upregulated by BAP1 loss through H3K27ac accumulation at the PROS1 locus [PMID:31766614, PMID:35954340]. Hereditary protein S deficiency, a thrombophilic disorder, results from loss-of-function mutations including missense variants causing intracellular misfolding and gross PROS1 gene deletions [PMID:11776305, PMID:19466456].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying the molecular basis of hereditary protein S deficiency established that PROS1 missense mutations cause disease through impaired protein folding and secretion rather than absent transcription.\",\n      \"evidence\": \"DNA sequencing of protein S-deficient families combined with platelet mRNA analysis and computational structural modeling\",\n      \"pmids\": [\"11776305\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Misfolding mechanism inferred from computational modeling without in vitro reconstitution or pulse-chase experiments\",\n        \"No functional rescue experiments to confirm causality of individual mutations\",\n        \"Intracellular degradation pathway for misfolded PROS1 not characterized\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that gross copy number variations (deletions, duplications) of the PROS1 gene account for a substantial fraction of hereditary protein S deficiency cases expanded the mutational spectrum beyond point mutations.\",\n      \"evidence\": \"MLPA and quantitative PCR with family segregation analysis in mutation-negative protein S-deficient kindreds\",\n      \"pmids\": [\"19466456\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Breakpoint sequences and recombination mechanisms underlying PROS1 CNVs not determined\",\n        \"Functional consequences of partial deletions versus complete deletions not distinguished at the protein level\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that PROS1 knockdown in glioblastoma cells induced apoptosis and reduced invasion established an autocrine pro-survival role for PROS1 in cancer, linking it upstream of TAM receptor and death receptor signaling.\",\n      \"evidence\": \"siRNA knockdown in LN18 glioblastoma cells with apoptosis, invasion, and gene expression readouts\",\n      \"pmids\": [\"27840905\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single cell line tested; generalizability unknown\",\n        \"Whether the survival effect operates through Tyro3 specifically was not resolved\",\n        \"FasL upregulation mechanism upon PROS1 loss not defined\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defining PROS1 as a functional TAM ligand on macrophages — acting through Mer and Tyro3 but not Axl, and recruiting PTP1b to Mer — resolved how tumor-derived PROS1 suppresses M1 macrophage polarization and anti-tumor immunity.\",\n      \"evidence\": \"CRISPR deletion of Pros1 in tumor cells, macrophages from Mer-KO/Tyro3-KO/Axl-KO/PTP1b-KO mice, co-immunoprecipitation of PTP1b-Mer, in vivo tumor models\",\n      \"pmids\": [\"29708510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct phosphatase substrates of PTP1b downstream of Mer-PROS1 not identified\",\n        \"Whether PROS1-Mer signaling differs from Gas6-Mer signaling at the level of PTP1b recruitment is unknown\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showing that PROS1 preferentially activates Tyro3/Erk whereas Gas6 preferentially activates Axl/Akt distinguished the signaling specificities of the two TAM ligands and explained PROS1's anti-apoptotic activity in cancer cells.\",\n      \"evidence\": \"Kinase phosphorylation assays, ProS1 ligand traps, warfarin treatment, and apoptosis assays across cancer cell lines with differential TAM receptor expression\",\n      \"pmids\": [\"31766614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Structural basis for PROS1's selectivity for Tyro3 over Axl not determined\",\n        \"In vivo validation of differential PROS1-Tyro3 versus Gas6-Axl signaling not performed\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Conditional myeloid knockout revealed that myeloid-derived PROS1 suppresses metastasis through MERTK-dependent regulation of Socs3/NF-κB, but IL-10 regulation is MERTK kinase-independent, establishing divergent downstream branches of PROS1-MERTK signaling.\",\n      \"evidence\": \"Myeloid-specific Pros1 conditional knockout mice, MERTK kinase inhibition, BMDM conditioned medium transfer, lung and breast tumor metastasis models\",\n      \"pmids\": [\"33848267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"MERTK kinase-independent mechanism controlling IL-10 not identified\",\n        \"Whether PROS1 from non-myeloid stromal sources contributes additively to metastasis suppression is unknown\",\n        \"Direct Socs3 regulation by MERTK (phosphorylation or transcription) not fully resolved\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking BAP1 loss to PROS1 epigenetic upregulation via H3K27ac accumulation at the PROS1 locus established a chromatin-level mechanism by which a tumor suppressor mutation drives immune evasion through the PROS1-MERTK axis.\",\n      \"evidence\": \"ChIP-seq for H3K27ac, RNA-seq, PROS1 depletion in BAP1-KO uveal melanoma cells with MERTK phosphorylation readout in co-cultured macrophages\",\n      \"pmids\": [\"35954340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether BAP1 directly deubiquitinates H2A at the PROS1 locus or acts indirectly through other chromatin remodelers not resolved\",\n        \"In vivo tumor immune evasion phenotype of PROS1 depletion in BAP1-null tumors not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural determinants of PROS1's selectivity for Tyro3/MERTK over Axl, the identity of PTP1b substrates downstream of PROS1-Mer, and the MERTK kinase-independent mechanism controlling IL-10 remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No co-crystal structure of PROS1 with any TAM receptor\",\n        \"PTP1b substrates in PROS1-Mer signaling not identified\",\n        \"MERTK kinase-independent IL-10 regulation mechanism unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"MERTK\",\n      \"TYRO3\",\n      \"PTPN1\",\n      \"BAP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PROS1 encodes Protein S, a vitamin K-dependent plasma glycoprotein that functions as a central anticoagulant regulator and immunomodulatory ligand. As a cofactor for activated protein C (APC), Protein S promotes inactivation of factors Va and VIIIa; it also directly inhibits Factor Xa and prothrombinase independently of APC, and enhances TFPI-mediated suppression of the tissue factor pathway by reducing the Ki of the FXa/TFPI complex approximately 10-fold [PMID:6239102, PMID:8428962, PMID:8146182, PMID:16488980]. Approximately 60% of circulating Protein S is complexed with C4b-binding protein (C4BP), which abrogates its APC cofactor activity; loss-of-function mutations and copy number variations in PROS1 cause hereditary protein S deficiency and recurrent venous thromboembolism [PMID:6454142, PMID:1534488, PMID:19466456]. Beyond hemostasis, Protein S binds phosphatidylserine on apoptotic cells to stimulate macrophage phagocytosis and signals through Mer and Tyro3 TAM receptors to suppress inflammatory cytokine production in dendritic cells and macrophages, thereby restraining innate and adaptive immune activation and modulating tumor immune evasion [PMID:12447359, PMID:23850380, PMID:29708510, PMID:33848267].\",\n  \"teleology\": [\n    {\n      \"year\": 1981,\n      \"claim\": \"The discovery that Protein S circulates in both free and C4BP-complexed forms established that its bioavailability is regulated by a stoichiometric interaction with complement component C4BP, linking coagulation and complement systems.\",\n      \"evidence\": \"Biochemical fractionation, barium citrate adsorption, and SDS-PAGE of human plasma\",\n      \"pmids\": [\"6454142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of C4BP binding on Protein S activity was not yet determined\", \"Identity of the C4BP subunit mediating the interaction was unknown\"]\n    },\n    {\n      \"year\": 1984,\n      \"claim\": \"Demonstration that Protein S is an essential cofactor for APC-mediated inactivation of factors Va and VIIIa, and that its deficiency causes venous thromboembolism, established the physiological anticoagulant role of PROS1.\",\n      \"evidence\": \"Functional protein S activity assay in plasma from deficient patients, clinical phenotyping\",\n      \"pmids\": [\"6239102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of cofactor enhancement of APC activity was unresolved\", \"Whether Protein S had APC-independent anticoagulant activity was unknown\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Cloning of human and bovine PROS1 cDNA revealed a unique multi-domain architecture—Gla domain, thrombin-sensitive region, four EGF-like repeats, and an SHBG-homologous C-terminus—that distinguishes it from serine protease coagulation factors and explains its non-enzymatic cofactor function.\",\n      \"evidence\": \"cDNA cloning from human and bovine liver libraries, direct protein sequencing (bovine)\",\n      \"pmids\": [\"2944113\", \"2940598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functions of individual domains (e.g., SHBG-like domain) were not mapped\", \"Molecular basis for C4BP and APC interactions remained undefined\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Detailed biochemical characterization established that the C4BP beta-chain is the sole Protein S binding site, that C4BP complexation abolishes APC cofactor activity, and that calcium binding to EGF-like domains is required for structural integrity, resolving how Protein S bioavailability is regulated.\",\n      \"evidence\": \"Domain-level binding studies, post-translational modification mapping, cofactor reconstitution assays\",\n      \"pmids\": [\"1833851\", \"1534488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how C4BP binding neutralizes APC cofactor function was unknown\", \"In vivo regulation of C4BP beta-chain expression was not addressed\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Discovery that Protein S directly binds and inhibits Factor Xa and Factor Va and suppresses prothrombinase activity independently of APC revealed a second, autonomous anticoagulant mechanism.\",\n      \"evidence\": \"Reconstituted binding assays (solid-phase and fluid-phase), FXa amidolytic activity assay, prothrombin conversion assay with purified components\",\n      \"pmids\": [\"8428962\", \"8146182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative physiological contribution of APC-independent vs APC-dependent anticoagulant activity was unclear\", \"Structural determinants of the Protein S–FXa interaction were not mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of Protein S as the serum factor that binds phosphatidylserine on apoptotic cells and stimulates macrophage phagocytosis extended its function beyond hemostasis into innate immune clearance.\",\n      \"evidence\": \"Immunodepletion of Protein S from serum, reconstituted macrophage phagocytosis assay with apoptotic lymphoma cells\",\n      \"pmids\": [\"12447359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor on macrophages mediating Protein S-stimulated phagocytosis was not identified\", \"Whether this function operates in vivo and its relationship to autoimmunity was unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Protein S was shown to enhance TFPI-mediated inhibition of the tissue factor pathway by reducing the Ki of TFPI for Factor Xa ~10-fold, identifying a third distinct anticoagulant mechanism independent of APC.\",\n      \"evidence\": \"Purified component coagulation assays, kinetic analysis of FXa inhibition by TFPI ± Protein S\",\n      \"pmids\": [\"16488980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain of Protein S responsible for TFPI enhancement was not mapped\", \"In vivo significance relative to APC cofactor function was not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstration that gross PROS1 copy number variations account for approximately one-third of mutation-negative hereditary protein S deficiency cases expanded the genetic basis of this thrombophilia beyond point mutations.\",\n      \"evidence\": \"MLPA and quantitative PCR in hereditary protein S-deficient families\",\n      \"pmids\": [\"19466456\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype–phenotype correlations for specific CNV types were limited\", \"Prevalence of CNVs across diverse populations was not determined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Conditional knockout of Pros1 in T cells revealed that T cell-derived Protein S signals through TAM receptors on dendritic cells to limit DC activation, establishing Protein S as a homeostatic negative feedback ligand bridging adaptive and innate immunity.\",\n      \"evidence\": \"T cell-specific Pros1 conditional KO mouse, DC activation assays, colitis model, confirmed PROS1 expression in human activated T cells\",\n      \"pmids\": [\"23850380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific TAM receptor (Mer vs Tyro3 vs Axl) mediating DC suppression was not fully resolved\", \"Downstream signaling cascade in DCs was not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CRISPR deletion of Pros1 in tumor cells and receptor-KO macrophage studies demonstrated that tumor-secreted Protein S suppresses macrophage M1 polarization via Mer and Tyro3 (not Axl), requiring PTP1b, directly linking Protein S to tumor immune evasion.\",\n      \"evidence\": \"CRISPR Pros1-KO tumor cells, Mer/Tyro3/Axl-KO and PTP1b-KO macrophages, in vivo tumor models\",\n      \"pmids\": [\"29708510\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural determinants of Protein S selectivity for Mer/Tyro3 over Axl were unknown\", \"Whether pharmacological targeting of Protein S–TAM axis is therapeutically viable was untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Myeloid-specific Pros1 deletion showed that macrophage-derived Protein S suppresses metastatic seeding by restraining pro-inflammatory and pro-tumorigenic cytokine production via MERTK–Socs3/NF-κB signaling, revealing a cell-autonomous immunomodulatory role in the tumor microenvironment.\",\n      \"evidence\": \"Myeloid-specific Pros1 cKO mouse, lung and breast metastasis models, BMDM conditioned medium assays, MERTK kinase inhibition\",\n      \"pmids\": [\"33848267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of myeloid vs tumor-derived PROS1 to net immunosuppression in tumors was not dissected\", \"PROS1-mediated regulation of IL-10, which was MERTK-independent, remains mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"In uveal melanoma, BAP1 loss was shown to epigenetically upregulate PROS1 (via H3K27ac accumulation), and elevated tumor-secreted PROS1 activates MERTK on CD163+ macrophages to promote an immunosuppressive M2 microenvironment, linking epigenetic deregulation to Protein S-mediated immune evasion.\",\n      \"evidence\": \"ChIP-seq, scRNA-seq, co-culture MERTK phosphorylation assay, siRNA depletion, patient tumor IHC\",\n      \"pmids\": [\"35954340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BAP1-driven PROS1 upregulation is generalizable to other BAP1-mutant cancers is unknown\", \"Therapeutic blockade of PROS1–MERTK axis in uveal melanoma has not been tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"High-resolution structural data for Protein S—including full-length structure, the Protein S–APC interface, and the Protein S–TFPI–FXa ternary complex—remain unavailable, limiting rational drug design and a unified structural understanding of its multi-partner interactions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length crystal or cryo-EM structure of Protein S\", \"Structural basis of selectivity for Mer/Tyro3 versus Axl as TAM ligand is not resolved\", \"Mechanism by which C4BP binding neutralizes APC cofactor function at the structural level is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 5, 7, 8, 12]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [14, 16, 17, 18, 19]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 5, 6, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 6, 10, 14, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [1, 5, 7, 8, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 14, 16, 18, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 16, 17, 18, 19]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 15, 17]}\n    ],\n    \"complexes\": [\n      \"Protein S–C4BP complex\"\n    ],\n    \"partners\": [\n      \"C4BPB\",\n      \"TFPI\",\n      \"MERTK\",\n      \"TYRO3\",\n      \"F5\",\n      \"F10\",\n      \"PROC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}